



Vivimed

For Immediate Release

August 5, 2020

**Vivimed announces the receipt of export order for supply of “Favulous” tablets 200 mg (Favipiravir)**

**Hyderabad, India, August 5, 2020** – Vivimed Labs Limited (“Vivimed” or the Company), a niche Specialty Chemicals and Pharmaceuticals company, announced today, the manufacturing of “Favulous” tablets 200 mg (Favipiravir) against export order. Favulous tablets 200 mg (Favipiravir) is used for the treatment of mild to moderate cases of Covid-19 . Favipiravir is the only oral anti-viral treatment approved in various countries for the potential treatment of patients with mild to moderate Covid-19 disease. The initial Export order Value is worth over INR 100 Million. we expect to receive further repeat orders during the Year.

\*\*\* \*\* \*

Commenting on the launch, Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said, “With over 300,000 Covid-19 cases being reported daily thought out the world, there is an urgent need to provide more treatment options to healthcare professionals. We are launching “Favulous” at an economical price to make the drug accessible to more and more patients thereby ensuring good health and reducing their financial burden. This is in line with our continuous efforts to support world’s pandemic response.”

The company will work closely with the various governments and medical community to ensure availability of “Favulous” to patients across the world.

For further information on Vivimed, visit [www.vivimedlabs.com](http://www.vivimedlabs.com)

\*\*\* \*\* \*

**Safe Harbour**

This release contains “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed’s future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Vivimed undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For further information please contact:

**Company Contact:**

K.Yugandhar

Company Secretary & Compliance officer

Vivimed Labs Limited (CIN No: L02411KA1988PLC009465)

Corporate office: Northend Complex, Road No.2, Banjara Hills, Hyderabad, India

Phone: 040-66086608, Email: [yugandhar.kopparthi@vivimedlabs.com](mailto:yugandhar.kopparthi@vivimedlabs.com)

For VIVIMED LABS LTD.

*K. Yugandhar*  
K. YUGANDHAR  
Company Secretary  
ACS No. 19315